KNIGHT THERAPEUTICS INC.

(GUD)
  Rapport
Temps Différé Toronto Stock Exchange  -  26/05 22:00:00
5.350 CAD   -0.56%
24/05Thérapeutique Knight conclue des accords de licence et d'approvisionnement exclusifs avec Rigel Pharmaceuticals pour commercialiser le Fostamatinib en Amérique latine
GL
12/05Knight Therapeutics annonce une perte par action de 0,16 $ au premier trimestre et met à jour ses prévisions de revenus
MT
12/05Knight Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
CI
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur KNIGHT THERAPEUTICS INC.
24/05Knight Therapeutics Inks Agreements with Rigel Pharmaceuticals to Commercialize Fostama..
24/05KNIGHT THERAPEUTICS BRIEF : Enters into Exclusive License and Supply Agreements with Rigel..
24/05Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Phar..
24/05Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Phar..
12/05Knight Therapeutics Reports Q1 Loss Per Share $0.16, Updates Revenue Guidance
12/05TRANSCRIPT : Knight Therapeutics Inc., Q1 2022 Earnings Call, May 12, 2022
12/05Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31,..
12/05Knight Therapeutics Reports First Quarter 2022 Results
12/05Knight Therapeutics Reports First Quarter 2022 Results
12/05Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2022
12/05Knight Therapeutics and Helsinn Healthcare SA Enters into Exclusive License, Distributi..
12/05Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distributio..
12/05Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distributio..
12/05Knight to Present at the 2022 RBC Capital Markets Global Healthcare Conference in New Y..
12/05Knight Therapeutics Inc. announces voting results from the Annual Meeting
12/05Knight Therapeutics Inc. announces voting results from the Annual Meeting
11/05TRANSCRIPT : Knight Therapeutics Inc. - Shareholder/Analyst Call
05/05Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call
05/05Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call
26/04Knight to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
30/03Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and Licens..
29/03Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million, License a..
25/03Knight Therapeutics Inc. places on The Globe and Mail's third-annual Women Lead Here be..
24/03TRANSCRIPT : Knight Therapeutics Inc., Q4 2021 Earnings Call, Mar 24, 2022
24/03Knight Therapeutics Swings to a Fourth-Quarter Loss on Non-Cash Charges
24/03Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 12, ..
24/03Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, ..
24/03KNIGHT THERAPEUTICS BRIEF : For fiscal 2022, Knight Expects to Generate $260 to $265 milli..
24/03KNIGHT THERAPEUTICS BRIEF : Reports Q4 Net Loss $8,3 Million Vs Income of Near 8.233 Milli..
24/03Knight Therapeutics Reports Fourth Quarter and Year-End 2021 Results and Provides 2022 ..
24/03Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December..
24/03Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal 2022
24/03NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
17/03Notice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference Call
06/01Knight Therapeutics Announces Approval of Breast Cancer Drug, Halaven, in Colombia
06/01KNIGHT THERAPEUTICS BRIEF : Announces Approval of Halaven in Colombia
06/01Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia
06/01Knight Therapeutics Inc. anuncia la aprobación de Halaven® en Colombia
06/01Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia
05/01Knight Therapeutics Inc. Announces Approval of Lenvima in Colombia
04/01Knight Therapeutics Reports Approval of Lenvima in Colombia
04/01Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia
04/01Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia
2021Knight to Present at Stifel GMP's The Future of Healthcare Conference
2021Knight to Present at Stifel GMP's The Future of Healthcare Conference
2021Knight Therapeutics Reports Q3 Basic Net Loss $0.07
2021TRANSCRIPT : Knight Therapeutics Inc., Q3 2021 Earnings Call, Nov 11, 2021
2021Knight Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months..
2021Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 12, ..
2021Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, ..
2021Knight Therapeutics Reports Third Quarter 2021
2021Notice of Knight Therapeutics Third Quarter 2021 Results Conference Call
2021Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call
2021Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call
2021INCYTE : Signs Supply, Distribution Deal for Tafasitamab, Pemigatinib in Latin America
2021KNIGHT THERAPEUTICS : in Supply and Distribution Agreement with NASDAQ's Incyte for Tafasi..
2021KNIGHT THERAPEUTICS BRIEF : Enters into Exclusive Supply and Distribution Agreement with N..
2021INCYTE : Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with ..
2021Knight Therapeutics Inc. Enters into Exclusive Supply and Distribution Agreement with I..
2021KNIGHT THERAPEUTICS : Reports Second Quarter 2021
2021NORTH AMERICAN MORNING BRIEFING : Weak Chinese -3-
2021TRANSCRIPT : Knight Therapeutics Inc., Q2 2021 Earnings Call, Aug 13, 2021
2021KNIGHT THERAPEUTICS : Posts Q2 EPS of C$0.23; Revenue Reaches Record C$65.8 Million
2021Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, ..
2021KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Posts Q2 EPS Basic C$0.2..
2021KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Reports Q2 Revenue C$65...
2021NORTH AMERICAN MORNING BRIEFING : Blockbuster -3-
2021Notice of Knight Therapeutics' Second Quarter 2021 Results Conference Call
2021Knight Therapeutics Inc.'s Equity Buyback announced on July 10, 2020, has expired with ..
2021UPDATE : Knight Therapeutics Up 3% as Launches Normal Course Issuer Bid
2021KNIGHT THERAPEUTICS : Launches Normal Course Issuer Bid
2021Knight Therapeutics Inc. announces an Equity Buyback for 10,267,956 shares, representin..
2021KNIGHT THERAPEUTICS : Announces Normal Course Issuer Bid
2021Knight Therapeutics Inc. authorizes a Buyback Plan.
2021Knight Therapeutics Gets Health Canada Approval for Neratinib
1  2  3  4  5  6  7Suiv.
Prochain événement sur KNIGHT THERAPEUTICS INC.